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ABSTRACT 
Aims 
To assess the impact of a Medication Review with Follow-up (MRF) service provided in 
community pharmacy to aged polypharmacy patients on the number of medication-related 
hospital admissions and to estimate the effect on hospital costs. 
Methods 
This was a sub-analysis of a cluster randomized controlled trial carried out in 178 
community pharmacies in Spain. Pharmacies in the intervention group (IG) provided a 
comprehensive medication review during six months. Pharmacists in the comparison group 
(CG) delivered usual care. For the purposes of this sub-analysis, an expert panel of three 
internal medicine specialists screened the hospitalisations occurring during the main study, 
in order to identify medication-related hospitalisations. Inter-rater reliability was measured 
using Fleiss´ kappa. Hospital costs were calculated using diagnosis related groups. 
Results 
1403 patients were included in the main study and they had 83 hospitalisations. 42 
hospitalisations (50.6%) were medicine-related, with a substantial level of agreement 
among the experts (kappa=0.65; 95%CI: 0.52, 0.78; p<0.01). The number of medication-
related hospitalisations was significantly lower in patients receiving MRF (IG: 11; GC: 31, 
p=0.042). The probability of being hospitalised was 3.7 times higher in the CG (odds ratio: 
3.7; 95%CI: 1.2, 11.3; p=0.021). Costs for a medicine-related hospitalisation were €6,672. 
Medication-related hospitalisation costs were lower for patients receiving MRF [IG: €94 (SD 
917); CG: €301 (SD 2,102); 95% CI: 35.9, 378.0; p=0.018]. 
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Conclusion 
MRF provided by community pharmacists might be an effective strategy to balance the 
assurance of the benefit from medications and the avoidance of medication-related 
hospitalisations in aged patients using polypharmacy. 
 
What is known about this subject  
- Medication-related hospital admissions are a significant problem in aged 
polypharmacy patients 
- The evidence of the impact of professional pharmacy services on hospital admissions 
remains uncertain 
What this study adds  
- The percentage of medication-related hospital admissions was significantly lower in 
patients receiving Medication Review with Follow-up (26.2% vs 73.8%, p<0.05) 
- The probability of being hospitalised was 3.7 times higher in the comparison group 
than in the intervention group (p<0.05). 
- Medication-related hospitalisation costs were lower for patients receiving MRF [IG: 
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INTRODUCTION 
Morbidity associated with the use of medicines represents an important clinical burden [1-
6]. A systematic review found that adverse events during hospital admission affect almost 
one in every ten patients, with 50% of them being preventable [2]. Between 0.1% and 54% 
of hospital admissions are medication-related with 20% being most common. Of these 
admissions 50% are preventable, and most of them involve the elderly population [3, 5-7]. 
The economic burden arising from healthcare resource consumption associated with drug-
related morbidity and mortality in ambulatory care in the U.S. was estimated to be $177.4 
billion (2000 year data) [8]. In The Netherlands potentially preventable medication-related 
hospital admissions cost more than €94 million in 2006 or €5461 for each hospital admission 
[9].  
An ageing population and the use of polypharmacy are risk factors for suffering not only 
drug related problems (DRPs) [1] but also medication-related hospital admissions [6]. 
Therefore, aged patients using polypharmacy are bound to benefit from health care 
interventions aimed at resolving DRPs. 
Professional or cognitive pharmacy services are “an action or set of actions undertaken in or 
organised by a pharmacy, delivered by a pharmacist or other health practitioner, who 
applies their specialised health knowledge personally or via an intermediary, with a 
patient/client, population or other health professional, to optimise the process of care, with 
the aim to improve health outcomes and the value of healthcare” [10]. Professional 
pharmacy services are an effective strategy to avoid and resolve DRPs as well as negative 
clinical outcomes related to medicines. However, their effectiveness on reducing hospital 
admissions has not been clearly established [11]. 
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A nationwide research project called “conSIGUE Program” was undertaken in Spain with the 
aim of assessing the economic, clinical and humanistic impact of a Medication Review with 
Follow-up service (MRF), provided in community pharmacies to aged polypharmacy patients 
[12]. MRF is a professional service aimed at detecting DRP in order to identify, prevent and 
solve negative clinical outcomes related to medicines [13]. The conSIGUE Program obtained 
promising results in terms of hospital admission rates, as shown in the non-peer reviewed 
report published by the Spanish General Council of Ofﬁcial Colleges of Pharmacists [12]. 
However, a more in-depth analysis was needed to analyse the cause and effect relationship 
between medication use and hospitalisations. The aims of the present study were to assess 
the impact of community pharmacy-led Medication Review with Follow-up provided to aged 
polypharmacy patients on the number of medication related hospital admissions and 
estimate the effect on hospital costs. 
 
METHODS 
The main study was a cluster randomized controlled trial aimed at assessing the clinical, 
economic and humanistic impact of the Medication Review with Follow-up performed in 
community pharmacy on aged polypharmacy patients. The aim of the retrospective sub-
analysis reported in this manuscript was to analyse the impact of the MRF on hospital 
admissions. Therefore, hospital admissions occurred during the main study were retrieved 
and an expert panel was convened in order to separate those hospital admissions related to 
medicines from hospital admissions not related to medicines (see Figure 1).” 
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Methods of the main study to assess the clinical, economic and humanistic outcomes of the 
Medication Review with Follow-up in aged polypharmacy patients 
Study design 
The conSIGUE project was a cluster randomized controlled trial carried out in 178 
community pharmacies in 4 Spanish provinces (Guipuzcoa, Granada, Las Palmas and 
Tenerife) with 6-month follow-up in each province between 2011 and 2013. 
Study population: pharmacies and patients 
All the community pharmacies located in the 4 provinces (independent of the urban or rural 
setting and size of the pharmacy) received an invitation to participate in the study from the 
provincial Official Associations of Pharmacists, with all the respondents enrolled. Each 
pharmacy was required to recruit up to ten patients with the following criteria: aged 
patients (65 years or older), using polypharmacy (five or more medications for at least 6 
months) and with the ability to complete the EuroQol 5D questionnaire. Products registered 
as medicines in Spain, prescribed and over the counter, were considered medications [14]. 
Informed consent was obtained from all patients, who were provided with an information 
sheet prior to the beginning of the study. 
Pharmacies were the cluster unit of randomisation in order to minimise contamination bias. 
After their agreement to participate, pharmacies were randomly allocated by an 
independent researcher to the intervention group (IG) or comparison group (CG) using a 
computer-generated list of random numbers (ratio 1:1) and stratified by province. Neither 
patients nor pharmacists could be blinded due to the characteristics of the intervention. 
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Sample size was estimated for this main study and not for the sub-analysis; therefore 
caution is required when interpreting the results. 
The study protocol was approved by the Clinical Research Ethics Committee of the Virgen de 
las Nieves Hospital of Granada, Spain (Ref: 09/123-09/10-06). 
MRF and study groups 
Pharmacists allocated to the IG provided the MRF service according to national guidelines 
[13], whereas pharmacists in  the CG provided usual care.  
The MRF service starts with a comprehensive interview undertaken in a private area of the 
pharmacy. The pharmacist collects relevant information about the patient’s health 
problems, medicines used, clinical and biological parameters (gathered through medical 
records provided by the patient or measured in the pharmacy), medication use, lifestyle 
habits, and concerns about diseases and medications. Pharmacists also assess the level of 
control of health problems by using information referred by patients’ and/or clinical and 
biological parameters, depending on the type of health problem (i.e. pain vs 
hyperlipidaemia) and classify every health problem as controlled, uncontrolled or unknown. 
After performing a comprehensive medication review, the pharmacist identifies negative 
clinical outcomes related to medicines and DRPs. Subsequently, an action plan is agreed 
upon by the patient and the physician if required. This MRF service is focused on both 
patients’ outcomes and medication use process, and requires a commitment to follow-up. 
 
 
 This article is protected by copyright. All rights reserved. 
The usual care in Spanish community pharmacy settings consists of dispensing medicines 
prescribed by physicians and minor ailments advice [15]. 
Pharmacists in the IG received a 3-day training course covering the following topics: clinical 
management of aged patients, the MRF method, communication with patients and doctors, 
study protocol and documentation forms.  The training course was provided by members of 
the research group. All the lecturers were pharmacists and there was a clinical pharmacist, 
an expert in MRF methodology and an expert in communication. 
Pharmacists in the CG received a brief explanation about the study protocol and instructions 
to complete the documentation forms.  A specifically trained pharmacist called a practice 
change facilitator [16] helped pharmacists of the IG in the provision of the MRF, identifying 
barriers specific to each pharmacy and providing solutions. Additionally, the practice change 
facilitator ensured fidelity to the intervention and supported pharmacists of both study 
groups on queries about documentation forms. 
Study variables including patients’ sociodemographic characteristics, health-related quality 
of life, health problems, medication and use of health resources were collected on a 
monthly basis. In the CG, this occurred when patients attended the pharmacy to take their 
chronic medicines and in the IG, during the scheduled visits by the MRF service.  
 
Methods of the sub-analysis to assess the impact on hospital admissions of the Medication 
Review with Follow-up in aged polypharmacy patients 
Study design 
 This article is protected by copyright. All rights reserved. 
This retrospective sub-analysis consisted of an expert panel that analysed the clinical cases 
of patients hospitalised during the 6 month follow-up period of the previously described 
cluster randomized controlled trial, in order to identify medication-related hospital 
admissions. 
Study population: clinical cases of hospital admissions 
Clinical cases of those patients hospitalised during the 6 months of follow-up of the 
conSIGUE Program were retrieved. Patient´s self-reported information on hospitalisations 
was verified with the official records of the Spanish public health network. The list of 
diagnosis related groups (DRGs) was requested from the regional health directorates and 
public hospitals of the provinces participating in the main study. When the information 
reported by the patient and the information provided by regional health directorates or 
hospitals was discordant, the latter was accepted.  
Expert panel 
The expert panel consisted of three internal medicine specialists of the Donostia Hospital 
who had extensive professional experience. Internal medicine was considered to be suitable 
expertise in the field since it covers the diagnosis and treatment of a wide array of diseases, 
including chronic conditions and patients with multimorbidity.  
The expert panel was informed of the following concepts in a face to face meeting: the 
conceptual and methodological basis of the conSIGUE Program, the MRF service, the aim 
and methodology of this sub-analysis and patient clinical cases. Furthermore, the concept of 
DRP was clarified and experts were provided with the list of DRP contained in the national 
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guidelines [13] in order to avoid misconceptions between DRP and another terms like 
adverse drug reactions. 
The experts were provided with the following information about each clinical case: age, 
gender, health problems, level of control of the health problems, daily dose and frequency 
of the medicines used and the description of the DRG. Experts were blinded to the patient 
group allocation. Records were provided in paper and electronic format. 
Initially a pilot study was undertaken to familiarise experts with the rating process. Data of 
five patients of the main study were slightly modified in order to maintain the relevant 
characteristics and avoid the double assessment of these cases. All the experts rated the 
five cases independently, and sent the feedback to the research group.  
In the sub-analysis all hospital admission cases were assessed independently by each expert. 
The question posed to the experts was “Do you think that in this case, the hospital 
admission can be associated with a DRP?” The possible answers were “yes” or “no”. Each 
hospital admission was considered to be associated with a DRP when at least two out of the 
three experts stated so.  
The experts were requested to answer individually for each case, and the degree of 
agreement between them was later established. The inter-rater reliability (IRR) was 
measured using the Cohen´s kappa for every two raters [17] and the general agreement was 
assessed using the Fleiss kappa for multiple-raters [18]. 
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Outcome measures 
Medication-related hospital admission was the primary outcome of this sub-analysis. 
Hospital admissions were recorded in patients’ visits to the pharmacies, and the medication 
related ones were identified through the expert panel after the fieldwork. Kappa values 
ranging from 0.61 to 1 were considered as an acceptable inter-rater reliability (IRR) to 
measure the agreement among experts. 
The cost of hospital admissions estimated by DRG was a secondary outcome and the DRG 
were recorded after the fieldwork. Demographic variables were recorded at baseline. 
 Hospital costs 
DRGs of each hospital admission occurred during the 6 months of the main study were 
gathered from regional health directorates and public hospitals. DRGs are the system used 
in several countries for hospital reimbursement and in-hospital budgeting management 
[19]. For each hospital admission the description of the clinical problem led to the 
identification of the DRG and its designated costs by the Spanish government [20]. Costs 
were expressed in Euros and updated at 2014 prices using the Spanish consumer price 
index. 
Statistical analysis 
Categorical variables were expressed as frequencies and percentages and quantitative 
variables as means and standard deviations. Student´s t-test was used to analyse the 
differences between intervention and comparison groups, and Chi Square test or Fisher's 
exact test was used to assess the differences in frequency distribution. The risk of 
hospitalisation was calculated through a multivariate logistic regression model using the SAS 
 This article is protected by copyright. All rights reserved. 
GLIMMIX procedure. This analysis included a random intercept for pharmacy-nested within 
group to account for clustering of patients within pharmacies and was adjusted by 
covariates that could affect hospital admissions (age, gender and number of health 
problems). Differences between groups in hospital costs were analysed by hospital 
admission and by patient, and the latter ones adjusted by ANCOVA for the number of health 
problems. Statistical significance was set at p<0.05. Analyses were conducted using SPSS 
(Statistical Package for the Social Sciences v. 18.0 for Windows XP, Microsoft, U.S.), Epidat 
(Epidat v. 3.1, Galician Health Council and Pan American Health Organisation) and SAS 9.4 
(Statistical Analysis Software; SAS Institute, Cary, NC). 
 
RESULTS 
A total of 1403 patients (IG, n=688; CG, n=715) were included in the main study from 178 
pharmacies, with a mean of 7.9 (SD 2.4) patients per pharmacy. These patients reported 115 
hospital admissions, 83 of them were verifiable with official records and their DRGs were 
retrieved (Figure 1). These 83 hospitalisations were distributed over 50 pharmacies. Baseline 
characteristics of hospitalised patients are shown in table 1. None of the patients died 
during the 6-month follow-up. 
According to the expert panel 42 (50.6%) of the hospital admissions were medication-
related, with a kappa of 0.65 (95% CI: 0.52, 0.78; p<0.01). Significant differences for 
medication-related hospital admissions were identified between study groups (p=0.042); 31 
(73.8%) of the medication-related hospital admissions occurred in patients in the CG and 11 
(26.2%) in the IG. 
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The probability of being hospitalised was significantly higher in the CG compared with the 
IG. The unadjusted model showed an odds ratio (OR) of 2.7 (95% CI: 1.1, 6.7; p=0.036). 
When adjusting for other covariates (age, gender and number of health problems), the OR 
increased to 3.7 (95% CI: 1.2, 11.3; p=0.021) (Table 2). The cluster effect was inexistent 
(intracluster correlation coefficient=0). 
Table 3 shows the level of agreement between the three experts in regards to whether 
hospital admissions could be associated with a DRP or not. The multi-rater kappa revealed a 
substantial agreement degree (kappa=0.646; 95%CI: 0.52, 0.78; p<0.01) [21]. 
The total cost of the hospital admissions (n=83) was found to be €516,365. Medication-
related hospital admissions (n=42) amounted to €280,229 (IG: €64,846; CG: €215,383) and 
the mean cost per medication-related hospital admission was €6,672 (SD 5,298) [IG: €5,895 
(SD 4,496); CG: €6,948 (SD 5,597); p=0.578]. When the costs per group of the medication-
related hospital admissions were divided by the number of patients per group in the main 
study (IG: 688; CG: 715), medication-related hospital admission cost per patient receiving 
MRF was significantly lower than patients receiving usual care [IG: €94 (SD 917); CG: €301 
(SD 2,102); 95% CI: 35.9, 378.0; p=0.018]. When adjusted by number of health problems 
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DISCUSSION 
More than half of the hospitalisations (42 out of 83) of this sub-analysis were medication-
related. MRF seems to be an effective strategy to address medication-related hospital 
admissions, since the probability of being hospitalised in our study sample was 3.7 times 
higher in the CG compared with the IG (p<0.05). Medication-related hospital costs were 
significantly lower in patients receiving MRF. 
Several professional pharmacy services impacted positively on process indicators associated 
with the optimization of the patient´s medication management [11]. However, the impact of 
these services on outcome indicators remains unclear, as reported in a systematic review of 
systematic reviews published in 2013 [11]. This view has been endorsed in a number of 
subsequent systematic reviews and meta-analyses, in which the evidence of the impact of 
professional pharmacy services in hospital admissions is defined as conflicting, insufficient 
or uncertain or even null [22-28]. However, a large number of studies included in those 
reviews did not evaluate the association of hospital admissions with medicines; this fact 
may have biased the results obtained, since not all hospitalisations may have been 
associated with medications and therefore may not have been avoided through the 
provision of any professional pharmacy service.  
Additionally, different types of professional pharmacy services are compared. However, 
every service differs on its methodology, complexity, collaboration with other health care 
providers and level of responsibility assumed by the pharmacist [29]. Therefore it is logical 
that they are bound to achieve different outcomes. For example, the review carried out by 
Hatah et al. [23] performed a subgroup analysis showing that a medication review service 
had significant impact on reducing hospitalisations (OR 0.46, 95%CI: 0.26, 0.83), whereas 
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interventions focused on adherence did not demonstrate the same trend (OR 0.88, 95%CI: 
0.59, 1.32). Even the same type of professional pharmacy service may have different 
characteristics, rates of fidelity and implementation. Zermansky et al. [30] assessed a 
pharmacist-led medication review similar to this MRF. However, the practice change 
facilitator of this study could have increased pharmacists’ fidelity to the methodology and 
adherence to the guidelines of the MRF leading to the achievement of different outcomes. 
The study published by Ocampo et al [31] in which the service provided was exactly the 
same as in our study also found significant differences in hospital admissions.  
The assessment of patients with different baseline characteristics can also be a confounder 
when analysing the association between the provision of professional pharmacy services 
and hospitalisation rates. For example, the meta-analysis carried out by Viswanathan et al. 
[28] suggests that the evidence of the impact of Medication Therapy Management (MTM) 
on the outcomes of morbidity and mortality is insufficient. Nevertheless, they undertook a 
sub-analysis on a sample of patients suffering from diabetes mellitus or heart failure and it 
showed that MTM decreases the risk of being hospitalised and therefore hospitalisation 
costs. Interestingly, we observed that the baseline number of health problems and 
medicines used by patients in the sub-analysis was much higher than in the whole sample of 
the main study [12]. It could be said that a MRF service might reduce hospitalisations in a 
more complex type of patient, with specific chronic illnesses or treatments. In the future, it 
would be interesting to identify the group of patients which could benefit the most from the 
MRF. 
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In this study, total costs of all the medication-related hospitalisations amounted to €280,229 
and the cost of a medication-related hospital admission was €6,672. Another recent study 
from the Netherlands estimated this cost as €5,461 [9] indicating some consistency across 
studies. The mean cost per hospital admission was similar in both study groups IG: €5,895 
(SD 4,496); CG: €6,948 (SD 5,597); p=0.578]. However, when distributing medication-related 
hospitalisation costs among all the patients who had been allocated to receive the MRF or 
usual care, costs were significantly lower in patients receiving MRF [IG: €94 (SD 917); CG: 
€301 (SD 2,102); p=0.018]. It can be concluded that the MRF avoids costs to the National 
Health System by means of reducing the number of hospital admissions rather than 
reducing the cost per hospitalisation. Several economic evaluations of professional 
pharmacy services provided in community pharmacy do not include the cost of hospital 
admissions [32-34]; it could be due to the difficulty of accessing these data from the 
community pharmacy. However, the measurement of this variable is encouraged as it could 
lead to the cost-effectiveness of the service. 
In the hospitalisation screening, the experts´ independency and blindness to the study group 
were essential to assure the quality of the results and minimize possible bias. IRR 
(kappa=0.646; 95%CI: 0.52, 0.78) reached the “substantial agreement” level in the scale 
proposed by Landis & Koch [21]. It is highly likely that a higher IRR could have been reached 
if full diagnosis had been available for the experts, instead of just DRG description. However, 
this kappa value can be considered acceptable. For instance, the STOPP/START criteria, 
which have been widely accepted and implemented in real practice, reached the same level 
of agreement [35]. 
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A large number of studies reporting the prevalence of medication-related hospitalisations 
have been published, although hospitalisation rates vary widely. A recently published 
literature review which sifted through 95 studies, found that they ranged from 0.1% to 54% 
[7]. However, percentages around 5.3% [3] and 19.4% [36] are more frequent. The 
percentage of medication-related hospitalisations in this sub-analysis is high (50.6%, n=42) 
since this study combines several criteria identified as reporting higher rates of 
hospitalisations [7]: aged patients, consideration of adverse drug events instead of adverse 
drug reactions, inclusion of all hospital admissions rather than only acute ones and 
screening of the hospital admissions through a medical chart. Additionally, polypharmacy 
could be another factor leading to more medication related-hospital admissions. 
The small number of hospital admissions may be the main limitation of this study. Due to 
the low frequency of the final outcome, this is a common limitation in studies analysing 
hospitalised patients after receiving a pharmacist-led intervention [37] and results must be 
interpreted with caution. However, the appropriate sample size could be almost 
unreachable as was the case in a previous study [38]. Even with few medication-related 
hospitalisations we found significant differences in both number and costs of admissions 
between groups, although confidence intervals were wide. 
There was a lack of concordance between some of the hospital admissions self-reported by 
patients and those recovered from health regional directorates and official hospital 
registrations. 25 of the self-reported hospital admissions in the CG and 7 in the IG were 
unverifiable. Causes of this discordance could include: an error in patients´ perception, 
hospital admissions in private hospitals or in different provinces to the ones where the study 
was undertaken. We verified patients’ self-reported data with official sources, but other 
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systems are needed in future studies to ensure the recovery of a greater number of hospital 
admissions. Furthermore, the retrospective design of the study limited the information 
available, and it prevented us from comprehensively assessing the preventability of the 
medication-related hospital admissions [6] and from considering other possible reasons for 
non-admission to hospital, such us admission to care homes. 
 
Overall, medicines are the most widely used technology to resolve and control health 
problems and they consume a substantial part of the healthcare budget. However, this 
study endorses that patients are suffering a high number of hospital admissions due to the 
ineffective and unsafe use of medicines. Policy decision makers should consider the 
implementation of strategies proven to avoid such events in order to optimize population 
health as well as healthcare resource allocation. A MRF service provided by community 
pharmacists might be an effective strategy to balance the assurance of the benefit from 
medications and the avoidance of medication-related hospitalisations in older people using 
polypharmacy. This study provides novel evidence on the positive impact of a MRF service 
on hospital admissions, increasing the well-being of the elderly and enhancing the allocation 
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Figure 1: Pharmacy, patient and hospital admission flow diagram in the main cluster 
randomized controlled trial and in the expert panel sub-analysis. 
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Table 1: Baseline characteristics of hospitalised patients. 
 IG CG P value 
Age (years, mean (SD)) 76.07 (6.62) 74.17 (6.07) 0.240 
Gender (female); n (%) 17 (60.71) 14 (40.00) 0.102 
Partner status (with partner); n (%)* 8 (28.60) 20 (57.10) 0.053 
Education; n (%)**    
   No formal education 6 (21.40) 5 (14.30) 
0.712 
   Completed primary education 8 (28.60) 14 (40.00) 
   Completed secondary education 4 (14.3) 7 (20.00) 
   Completed university education 2 (7.10) 1 (2.9) 
Number of medicines used (mean (SD)) 8.32 (2.40) 7.74 (3.42) 0.450 
Number of health problems (mean (SD)) 6.57 (2.20) 5.23 (1.91) 0.012 
IG: intervention group (n=28); CG: comparison group (n=35).*Missing values: IG =5; CG=2. **Missing values: IG=8; CG=8. 
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Table 2: Multivariate logistic regression analysis to assess the effect of Medication Review with 
Follow-up on medication-related hospital admissions 
 Adjusted OR 95% CI P value 
     Group (IG  CG) 3.747 1.241-11.319 0.021 
          Age 1.004 0.933-1.080 0.915 
          Gender 0.762 0.290-2.006 0.571 
          Number of health problems 1.180 0.900-1.548 0.222 
IG: intervention group; CG: comparison group; OR: odds ratio; CI: Confidence Interval.  
Raw OR (simple logistic regression analysis): 2.7 (95%CI: 1.1-6.7; p=0.036). Adjusted OR (simple logistic regression 




Table 3: Inter-rater reliability between each pair of rater and overall agreement by answering whether hospital 
admission could be associated with drug related problems or not. 
Raters Agreement (%) Kappa statistic 95%CI 
Rater 1 vs Rater 2 83.13 0.667
 a
 0.51-0.82 
Rater 1 vs Rater 3 81.93 0.639
 a
 0.48-0.80 
Rater 2 vs Rater 3 81.93 0.637
 a
 0.47-0.80 







Fleiss´ kappa. Kappa <0.0 Poor agreement, kappa 0.0-0.20 Slight agreement, kappa 
0.21-0.40 Fair agreement, kappa 0.41-0.60 Moderate agreement, kappa 0.61-0.80 Substantial agreement, 0.81-1.0 Almost 
perfect agreement [21]. 
 
 
 
